Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th

11/3/22 7:00:00 AM ET

Medical/Dental Instruments

Health Care

Get the next $QNRX alert in real time by email

ASHBURN, Va., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today updated timing for its third quarter 2022 business update conference call and webcast. The conference call and webcast will now take place at 10:00am ET on Thursday November 10^th, 2022. The third quarter 2022 financial results will be reported before the open of the financial markets on the same day, Thursday November 10, 2022.

The live call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international).

The live and archived webcast of the call will be available on the Quoin Pharmaceuticals website under the Investors section: https://investors.quoinpharma.com/news-and-events/events-and-presentations

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact:

Investor Relations

PCG Advisory

Stephanie Prince

[email protected]

(646) 863-6341

Get the next $QNRX alert in real time by email

Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th

Chat with this insight

Recent Analyst Ratings for
$QNRX

$QNRX
Financials

Live finance-specific insights

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

$QNRX
Press Releases

Fastest customizable press release news feed in the world

Quoin Pharmaceuticals Releases Second Episode of its "Living with Netherton" Series, as part of its ongoing NETHERTON NOW awareness campaign

Quoin Pharmaceuticals Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

$QNRX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

$QNRX
SEC Filings

Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders

Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders

SEC Form EFFECT filed by Quoin Pharmaceuticals Ltd.

$QNRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

$QNRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th

Chat with this insight

Recent Analyst Ratings for $QNRX

$QNRX Financials

Live finance-specific insights

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

$QNRX Press Releases

Fastest customizable press release news feed in the world

Quoin Pharmaceuticals Releases Second Episode of its "Living with Netherton" Series, as part of its ongoing NETHERTON NOW awareness campaign

Quoin Pharmaceuticals Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

$QNRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

$QNRX SEC Filings

Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders

Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders

SEC Form EFFECT filed by Quoin Pharmaceuticals Ltd.

$QNRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

$QNRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

Recent Analyst Ratings for
$QNRX

$QNRX
Financials

$QNRX
Press Releases

$QNRX
Insider Purchases

$QNRX
SEC Filings

$QNRX
Large Ownership Changes

$QNRX
Insider Trading